Adding recent findings to this topic, in colorectal carcinoma (CRC), both tumor and stroma-derived Gal-1 have been found to confer an immune privilege to the tumor by increasing the frequency and immunosuppressive activity of CD8+ Tregs in experimental models [150]. This evidence concerns the gene CD8A and neoplasm.